Skip to main content
. 2018 May 28;9:277. doi: 10.3389/fendo.2018.00277

Figure 2.

Figure 2

Potential therapies for patients with metastatic pheochromocytomas and paraganglioma (MPPG). This figure describes potential therapies for patients with MPPG. Some of these therapies are currently evaluated in clinical trials: 1axitinib, cabozantinib, lenvatinib, pazopanib, and sunitinib; 2iobenguane 131I, 177Lu-DOTATATE; 3PT2977; 4axitinib, cabozantinib, lenvatinib, pazopanib, and sunitinib; 5cabozantinib; and 6pembrolizumab.